R Van Laar is an employee and shareholder in Geneseq Biosciences. I Winship is a board member and shareholder in Geneseq Biosciences. S Fereday is consultant to Geneseq Biosciences. S King, R McCoy, M Saad, C Uzzell and A Landgren are employees of Australian Clinical Labs. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.